Volodymyr Tryndyak Ph.D.

Leadership Role

Research Biologist — Division of Biochemical Toxicology

Volodymyr Tryndyak, Ph.D.
(870) 543-7121
NCTRResearch@fda.hhs.gov

Back to NCTR Principal Investigator page

Background

Volodymyr P. Tryndyak received an M.S. degree in biochemistry from Lviv National University (Lviv, Ukraine) and a Ph.D. degree in oncology from the Institute of Experimental Pathology, Oncology and Radiobiology, of the National Academy of Sciences of Ukraine (Kyiv, Ukraine). In 2004, Dr. Tryndyak joined the Division of Biochemical Toxicology at FDA’s National Center for Toxicological Research (NCTR) as a postdoctoral fellow and was converted to an FDA research biologist in 2022. Dr. Tryndyak has published over 108 research articles and has served as a reviewer for more than 15 scientific journals.

Research Interests

Dr. Tryndyak conducts studies with emphasis on developing epigenetic biomarkers that can be used in epidemiological and clinical studies to identify individuals in the population who may be susceptible to specific diseases. His research focuses on the mechanisms applicable for the identification of agents with carcinogenic potential using in vivo and in vitro models to facilitate the assessment of risk to human health. Using high-throughput approaches, Dr. Tryndyak has investigated genetic and epigenetic alterations after carcinogen exposure to understand mechanisms of cancer development and to identify biomarkers, especially non-invasive biomarkers, of cancer progression. Considering the genetic and epigenetic diversity in the human population, individualized and targeted approaches are key aspects of his research. Using a multiparental Collaborative Cross mouse population model, Dr. Tryndyak investigated interindividual- and sex-specific variations in the development of nonalcoholic fatty liver disease (NAFLD) to better understand the molecular mechanisms and drivers of the disease development and molecular determinants of interindividual susceptibility to NAFLD. Progression of NAFLD may lead to liver cancer development and early identification of these factors may help to prevent liver cancer.

The biopersistence of environmental toxicants in humans and animals, such as short-chain perfluorinated alkyl substances (PFAS), is of great concern for the FDA. Dr. Tryndyak, in collaboration with NCTR and Center for Food Safety and Applied Nutrition researchers, is investigating the role of renal organic anion transporters in toxicokinetics of C6-fluorotelomer alcohol, a major impurity in PFAS, and its metabolites. The results of these studies will be used to construct a biologically based dose-response model for C6-fluorotelomer alcohol and its metabolites in humans and rodents.

Coronavirus disease 2019 (COVID-19) is a worldwide pandemic respiratory disease associated with high transmission rates and mortality. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The shedding of detectable viral RNA in the feces of infected individuals enables its detection in community wastewater. Dr. Tryndyak is conducting next-generation sequencing analysis of RNA extracted from wastewater collected in selected metropolitan areas of Arkansas to detect presence of SARS-CoV-2 virus, determine SARS-CoV-2 viral load, and identify any coronavirus variants of the local community. This will be a valuable public health tool worldwide as it allows the monitoring of the disease on a populational scale.

Professional Societies/National and International Groups

American Association for Cancer Research
Member
2005 – Present

Society of Toxicology
Member
2007 – Present

Selected Publications

Epigenetic Effects of Low-level Sodium Arsenite Exposure on Human Liver HepaRG Cells.
Tryndyak V.P., Borowa-Mazgaj B., Steward C.R., Beland F.A., and Pogribny I.P.
Arch Toxicol. 2020, 94(12):3993-4005.

Characterization of the Variability in the Extent of Nonalcoholic Fatty Liver Induced by a High-Fat Diet in the Genetically Diverse Collaborative Cross Mouse Model.
de Conti A., Tryndyak V., Willett R.A., Borowa-Mazgaj B., Watson A., Patton R., Khare S., Muskhelishvili L., Olson G.R., Avigan M.I., Cerniglia C.E., Ross S.A., Sanyal A.J., Beland F.A., Rusyn I., and Pogribny I.P.
FASEB J. 2020, 34(6):7773-7785.

Gene Expression and Cytosine DNA Methylation Alterations in Induced Pluripotent Stem-Cell-Derived Human Hepatocytes Treated with Low Doses of Chemical Carcinogens.
Tryndyak V., Borowa-Mazgaj B., Beland F.A., and Pogribny I.P.
Arch Toxicol. 2019, 93(11):3335-3344.

Gene Expression and DNA Methylation Alterations During Non-alcoholic Steatohepatitis-Associated Liver Carcinogenesis.
Dreval K., Tryndyak V., de Conti A., Beland F.A., and Pogribny I.P.
Front Genet. 2019, 10:486.

Effect of Aflatoxin B1, Benzo[a]pyrene, and Methapyrilene on Transcriptomic and Epigenetic Alterations in Human Liver HepaRG Cells.
Tryndyak V., Kindrat I., Dreval K., Churchwell M.I., Beland F.A., and Pogribny I.P.
Food Chem Toxicol. 2018, 121:214-223.

Identification of Chromatin-Accessible Domains in Non-Alcoholic Steatohepatitis-Derived Hepatocellular Carcinoma.
Dechassa M.L., Tryndyak V., de Conti A., Xiao W., Beland F.A., and Pogribny I.P.
Mol Carcinog. 2018, 57(8):978-987.

Cellular and Molecular Effects of Prolonged Low-Level Sodium Arsenite Exposure on Human Hepatic HepaRG Cells.
Dreval K., Tryndyak V., Kindrat I., Twaddle N.C., Orisakwe O.E., Mudalige T.K., Beland F.A., Doerge D.R., and Pogribny I.P.
Toxicol Sci. 2018, 162(2):676-687.

Furan-Induced Transcriptomic and Gene-Specific DNA Methylation Changes in the Livers of Fischer 344 Rats in a 2-year Carcinogenicity Study.
Tryndyak V., de Conti A., Doerge D.R., Olson G.R., Beland F.A., and Pogribny I.P.
Arch Toxicol. 2017, 91(3):1233-1243.

MicroRNA Changes, Activation of Progenitor Cells and Severity of Liver Injury in Mice Induced by Choline and Folate Deficiency.
Tryndyak V.P., Marrone A.K., Latendresse J.R., Muskhelishvili L., Beland F.A., and Pogribny I.P.
J Nutr Biochem. 2016, 28:83-90.

Genotoxic, Epigenetic, and Transcriptomic Effects of Tamoxifen in Mouse Liver.
de Conti A., Tryndyak V., Churchwell M.I., Melnyk S., Latendresse J.R., Muskhelishvili L., Beland F.A., and Pogribny I.P.
Toxicology. 2014, 325:12-20.

Interstrain Differences in the Severity of Liver Injury Induced by a Choline- and Folate-Deficient Diet in Mice are Associated with Dysregulation of Genes Involved in Lipid Metabolism.
Tryndyak V., de Conti A., Kobets T., Kutanzi K., Koturbash I., Han T., Fuscoe J.C., Latendresse J.R., Melnyk S., Shymonyak S., Collins L., Ross S.A., Rusyn I., Beland F.A., and Pogribny I.P.
FASEB J. 2012, 26(11):4592-602.

Plasma MicroRNAs are Sensitive Indicators of Inter-Strain Differences in the Severity of Liver Injury Induced in Mice by a Choline- and Folate-Deficient Diet.
Tryndyak V.P., Latendresse J.R., Montgomery B., Ross S.A., Beland F.A., Rusyn I., and Pogribny I.P.
Toxicol Appl Pharmacol. 2012, 262(1):52-9.

Coupling Global Methylation and Gene Expression Profiles Reveal Key Pathophysiological Events in Liver Injury Induced by a Methyl-Deficient Diet.
Tryndyak V.P., Han T., Muskhelishvili L., Fuscoe J.C., Ross S.A.. Beland F.A., and Pogribny I.P.
Mol Nutr Food Res. 2011, 55(3):411-8.

The Role of Epigenetic Events in Genotoxic Hepatocarcinogenesis Induced by 2-Acetylaminofluorene.
Pogribny I.P., Muskhelishvili L., Tryndyak V.P., and Beland F.A..
Mutat Res. 2011, 722(2):106-13.

E-cadherin Transcriptional Down-Regulation by Epigenetic and microRNA-200 Family Alterations is Related to Mesenchymal and Drug-Resistant Phenotypes in Human Breast Cancer Cells.
Tryndyak V.P., Beland F.A., and Pogribny I.P.
Int J Cancer. 2010, 126(11):2575-83.

Down-Regulation of the microRNAs miR-34a, miR-127, and miR-200b in Rat Liver During Hepatocarcinogenesis Induced by a Methyl-Deficient Diet.
Tryndyak V.P., Ross S.A., Beland F.A., and Pogribny I.P.
Mol Carcinog. 2009, 8(6):479-87.

Hepatic Epigenetic Phenotype Predetermines Individual Susceptibility to Hepatic Steatosis in Mice Fed a Lipogenic Methyl-Deficient Diet.
Pogribny I.P., Tryndyak V.P., Bagnyukova T.V., Melnyk S., Montgomery B., Ross S.A., Latendresse J.R., Rusyn I., and Beland F.A.
J Hepatol. 2009, 51(1):176-86.

Epigenetic Reprogramming of Liver Cells in Tamoxifen-Induced Rat Hepatocarcinogenesis.
Tryndyak V.P., Kovalchuk O., Muskhelishvili L., Montgomery B., Rodriguez-Juarez R., Melnyk S., Ross S.A., Beland F.A., and Pogribny I.P.
Mol Carcinog. 2007, 46(3):187-97.

Effect of Long-Term Tamoxifen Exposure on Genotoxic and Epigenetic Changes in Rat Liver: Implications for Tamoxifen-Induced Hepatocarcinogenesis.
Tryndyak V.P., Muskhelishvili L., Kovalchuk O., Rodriguez-Juarez R., Montgomery B., Churchwell M.I., Ross S.A., Beland F.A., and Pogribny I.P.
Carcinogenesis. 2006, 27(8):1713-20.

Histone H3 Lysine 9 and H4 Lysine 20 Trimethylation and the Expression of Suv4-20h2 and Suv-39h1 Histone Methyltransferases in Hepatocarcinogenesis Induced by Methyl Deficiency in Rats.
Pogribny I.P., Ross S.A., Tryndyak V.P., Pogribna M., Poirier L.A., and Karpinets T.V.
Carcinogenesis. 2006, 27(6):1180-6.

Identification of Differentially Methylated Sites Within Unmethylated DNA Domains in Normal and Cancer Cells.
Tryndyak V., Kovalchuk O., and Pogribny I.P.
Anal Biochem. 2006, 356(2):202-7.

Lab Members

Contact Information for all lab members:
(870) 543-7121
NCTRResearch@fda.hhs.gov

Igor Pogribny, M.D., Ph.D.
Research Biologist

Rose Willett, Ph.D.
ORISE Postdoctoral Fellow

Contact Information: Volodymyr Tryndyak; (870)543-7121